| Latest Xtl Biopharmaceuticals News Headlines |
| Date | Time | Source | |
| 10/31/2007 | 4:00AM | UKREG | Cancellation
Official List
31 October 2007
NOTICE OF CANCELLATION OF LISTING FROM THE OFFICIAL LIST
31/10/2007 8:00 AM
CANCELLATION
XTL Biopharmaceuticals Ld
The Financial Services Authority ("the FSA") cancels the securities set out
below from the Official List effective from 31/10/2007 8:00 AM at the request
of... More...>> |
| 10/29/2007 | 4:25AM | UKREG | XTL to Present at the Rodman & Renshaw Health Care Conf
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health
Care Conference
VALLEY COTTAGE, NEW YORK, October 29, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the
Company's Chief... More...>> |
| 10/25/2007 | 11:01AM | TFNF | XTL Biopharm agrees placement with institutional investors to raise 9.6 mln usd
XTL Biopharmaceuticals has agreed a private
placing with institutional investors, to raise 9.6 mln usd to fund the
completion of a phase IIb trial for its Bicifadine diabetic pain product.
XTL will issue 7.1 mln American depositary receipts representing 71 mln
ordinary shares. The transaction is conditional... More...>> |
| 10/25/2007 | 10:22AM | UKREG | XTL Announces $9.6 Mil Prvt Placement to Inst. Investors
XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to
Institutional Investors
Valley Cottage, New York, October 25, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) today announced that it has entered into
definitive... More...>> |
| 10/02/2007 | 11:30AM | UKREG | AGM / EGM Statements
AGM / EGM STATEMENTS
Valley Cottage, New York, October 2, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today that at its Annual General
Meeting and Extraordinary General Meeting held earlier today, all the
resolutions proposed to the shareholders were... More...>> |
| 09/26/2007 | 3:17AM | TFNF | XTL Biopharm says to appeal NASDAQ staff determination
XTL Biopharmaceuticals Ltd is to appeal a Staff
Determination from NASDAQ claiming it does not comply with the minimum 10 mln
usd shareholders' equity requirement. The NASDAQ ruling may see its ADR listing
transferred to the small cap market.
A hearing request will stay the suspension of the Company's ADRs... More...>> |
| 09/26/2007 | 2:27AM | UKREG | XTL to Appeal NASDAQ Staff Determination
XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to
the NASDAQ Capital Market
Valley Cottage, New York, September 26, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) today announced that on September 24, 2007,
the... More...>> |
| 09/25/2007 | 11:21AM | UKREG | XTL AGM / EGM POSTPONED UNTIL OCTOBER 2, 2007
XTL BIOPHARMACEUTICALS LTD. AGM / EGM POSTPONED UNTIL OCTOBER 2, 2007
Valley Cottage, New York, September 25, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today that its Annual General
Meeting ("AGM") and Extraordinary General Meeting ("EGM") was postponed for one
week in accordance... More...>> |
| 09/19/2007 | 12:20PM | UKREG | NOTICE OF SCHEDULE 13G FILING WITH THE US SEC
NOTICE OF SCHEDULE 13G FILING WITH THE UNITED STATES SECURITIES EXCHANGE
COMMISSION
Valley Cottage, New York, September 19, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) hereby notifies that it has just become
aware that... More...>> |
| 09/17/2007 | 4:27AM | TFNF | XTL Biopharmaceuticals presents new class of highly potent hepatitis C inhibitor
XTL Biopharmaceuticals Ltd said it presented a
new class of pre-clinical compounds with highly potent activity against the
hepatitis C virus at the International Symposium on Hepatitis C Virus & Related
Viruses in Glasgow, Scotland.
The company said the potency of these compounds was evaluated in a replicon
assay... More...>> |
| 09/17/2007 | 3:48AM | UKREG | NEW CL.-HIGHLY POTENT SM MOL INHIBITORS OF HCV-NS5A TRGT
XTL Biopharmaceuticals presents a new class of highly potent small molecule
inhibitors of hepatitis C affecting the NS5A target at an International
Scientific Conference
Valley Cottage, New York - September 17, 2007, XTL Biopharmaceuticals Ltd.
(NASDAQ:... More...>> |
| 09/11/2007 | 12:39PM | TFNF | UK small caps close on day's high; Ethanol Investments rebounds to end top riser
UK smaller companies closed on a session high
today, matching the positive mood of the wider market, with Ethanol Investments
bouncing back from earlier losses to end as top gainer.
At the close, the FTSE Small Cap index was 47.40 points firmer at 3,846.90,
while the FTSE 100 was 146.60 points higher at... More...>> |
| 09/11/2007 | 3:06AM | UKREG | Reminder: XTL to Hold Conf. Call Today at 8:30 am EDT
Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the
Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic
Neuropathic Pain
Valley Cottage, New York, September 11, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ:... More...>> |
| 09/10/2007 | 3:37AM | TFNF | XTL Biopharm starts phase IIb trial of Bicifadine for diabetic pain
XTL Biopharmaceuticals Ltd said it has started
a Phase IIb clinical trial of its Bicifadine drug for the treatment of diabetic
neuropathic pain.
The trial is aimed at demonstrating the efficacy of Bicifadine in diabetic
neuropathic pain and is designed to enrol about 330 patients.
TFN.newsdesk@thomson.com
faj/slm
COPYRIGHT
Copyright... More...>> |
| 09/10/2007 | 3:02AM | UKREG | Initiates Ph IIb Trial of Bicifadine for Diab Neuro Pain
XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the
Treatment of Diabetic Neuropathic Pain
Company to Hold a Conference Call Tomorrow (Tuesday) at 8:30 am EDT to Discuss
the Clinical Trial... More...>> |
| 09/06/2007 | 3:20AM | UKREG | Presentation of Novel Pre-Clinical Inhibitors of HCV
XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors
of Hepatitis C at an Upcoming International Scientific Conference
Oral presentation will be held on September 13, 2007 at the 14th International
Symposium on Hepatitis C Virus & Related Viruses to be held in Glasgow... More...>> |
| 09/05/2007 | 11:08AM | UKREG | Correction: XTL to Present at the Arch Investment Conf.
11:30am replaces the incorrect 11:30pm
XTL Biopharmaceuticals to Present at the Arch Investment Conference
Valley Cottage, New York, September 5, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the
acquisition, development and commercialization... More...>> |
| 09/05/2007 | 2:39AM | UKREG | XTL to Present at the Arch Investment Conference
XTL Biopharmaceuticals to Present at the Arch Investment Conference
Valley Cottage, New York, September 5, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the
acquisition, development and commercialization of therapeutics for the
treatment of unmet... More...>> |
| 08/28/2007 | 5:27AM | TFNF | XTL Biopharm says NASDAQ says co no longer qualifies for Global Market listing
XTL Biopharmaceuticals Ltd said it has received
a letter from NASDAQ indicating XTL no longer complies with the minimum 10 mln
usd shareholders' equity requirement for continued listing on The NASDAQ Global
Market.
The biopharmaceutical company said NASDAQ had sent the letter based on XTL's
financial statements... More...>> |
| 08/28/2007 | 4:46AM | UKREG | Processing Fees on ADRs to be Waived for Two Months
Processing Fees on ADRs to be Waived for Two Months
Valley Cottage, New York, August 28, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the
acquisition, development and commercialization of therapeutics for the
treatment of unmet medical... More...>> |